Bayer’s Zieler On The Power Of Real World Data, Asia Pacific Outlook

Claus Zieler, senior vice president and head of commercial operations, Bayer pharmaceuticals division Asia Pacific, tells Scrip why real world data is “very powerful” as more stakeholders including physicians look beyond just randomized clinical trial data. Zieler also underscores the German multinational’s intent to give “special attention” to the fast-growing Asia Pacific region.

The Asia Pacific (APAC) is a significant contributor to Bayer AG ’s pharmaceutical earnings and Claus Zieler, senior vice president and head of commercial operations, Bayer pharmaceuticals division Asia Pacific, indicates that the German multinational is keen to sustain the momentum in the region. He maintains an upbeat tenor for a basket of products including Xarelto (rivaroxaban) and Eylea (aflibercept), for which Bayer recently ramped up its sales expectations, but prefers not to be drawn into specifics on any potential headwinds in the region as a result of the emerging geopolitical situation.

In an interview with Scrip in Singapore last month, Zieler also underscored the value of real world data in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.